FDA Bans DMAA From Dietary Supplements, Issues Consumer Warning

|
Irvin Jackson

Add Your Comments

Federal health officials are warning consumers that a popular stimulant found in some sports performance drinks and other dietary supplements may cause heart attacks and other cardiovascular problems. 

The FDA is currently attempting to completely remove dimethylamyalmine (DMAA) from the market, and the agency issued a consumer warning on April 11, reporting that it has received at least 60 reports of illnesses and deaths associated with the ingredient.

DMAA is typically added to weight loss and muscle-building supplements, but the FDA says that the substance is too dangerous to be placed in dietary supplements.

Do You Know about…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Spinal-Cord-Stimulation-Lawsuit
Spinal-Cord-Stimulation-Lawsuit

Do You Know About…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

It is illegal to use DMAA in dietary supplements, the FDA warns. The additive can cause elevated blood pressure, heart attack, shortness of breath, and tightening of the chest. DMAA side effects can be even more dangerous when it is taken with caffeine the agency reports.

The consumer warning comes about a year after the FDA sent warning letters to ten companies that added DMAA to dietary supplements, ordering them to stop selling those products, all of which were sports performance drinks. All but one, USP Labs, LLC, has complied.

USP Labs has responded to the FDA letters by submitting published studies challenging the FDA’s determinations about the risks of DMAA. However, the FDA says it found the information USP provided to be insufficient to justify the use of DMAA. The agency is now preparing a formal response to the company.

As the FDA works to get DMAA off the market, it is warning consumers not to use products containing the additive, and warns that companies used a variety of names for DMAA, including:

  • 1,3-DMAA
  • 1,3-Dimethylamylamine
  • 1,3-Dimethylpentylamine
  • 2-Amino-4-methylhexane
  • 2-Hexanamine
  • 4-Methyl-2-hexanamine
  • 4-Methyl-2-hexylamine
  • 4-methyl- (9CI)
  • Dimethylamylamine
  • Geranamine
  • Methylhexanamine
  • Methylhexanenamine

The presence of Pelargonium graveolens extract or Geranium extract are also potential indicators that a product contains DMAA, the FDA warns.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.

Tags: Dietary Supplement, DMAA, Heart Attack, Hypertension
Image Credit: |

More Lawsuit Stories

0 Comments

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Medtronic SCS Lawsuit Alleges Intellis LT Neurostimulator Caused Worsening Pain
An Illinois woman has joined a growing number of plaintiffs alleging that the Medtronic Intellis neurostimulator, and similar devices, may fail to relieve chronic pain and instead lead to worsening complications.
Court Outlines Plan To Prepare Suboxone Tooth Decay Lawsuits for Trial in Early 2028
Four Suboxone tooth decay lawsuits will eventually be selected and prepared for bellwether trials set to begin in March 2028, according to a court order.
Hair Relaxer Class Action Lawsuit Certification Sought For Medical Monitoring Claims
A federal judge is being asked to certify seven hair relaxer class action lawsuits seeking medical monitoring for users, following studies that link the products to an increased risk of cancer.